The earnings call highlighted significant clinical progress, particularly with CX-2051, and a strong financial position, despite a decrease in revenue and some adverse events in trials. The company's focused pipeline development and strategic financial planning were positively emphasized.

Company Guidance -

Q3 2025

During CytomX Therapeutics' second-quarter 2025 financial results call, several key metrics were highlighted. CX-2051, a PROBODY antibody drug conjugate targeting EpCAM, showed promising initial Phase I data in colorectal cancer (CRC), with a 28% confirmed overall response rate and 94% disease control in 18 efficacy evaluable patients. The study also demonstrated a progression-free survival of 5.8 months. To further validate these results, dose expansions at 7.2, 8.6, and 10 mg/kg are underway, aiming for an updated dataset from approximately 70 patients by Q1 2026. Financially, CytomX ended the quarter with $158.1 million in cash, driven by a $100 million follow-on offering, ensuring a runway through Q2 2027. The company's revenue was $18.7 million, a decrease from $25.1 million in Q2 2024, attributed to completed performance obligations in collaborations with BMS and Amgen, and decreased activity with Moderna. Operating expenses were reduced to $19.9 million, with R&D expenses at $13.3 million, both showing significant year-over-year decreases.

Encouraging Clinical Data for CX-2051

CX-2051 demonstrated a 28% confirmed overall response rate, 94% disease control, and 5.8 months of preliminary progression-free survival in the first 18 efficacy evaluable patients, significantly exceeding current benchmarks for fifth-line CRC treatment.

Strong Financial Position

CytomX completed a $100 million follow-on offering, providing a cash runway to the second quarter of 2027, supporting ongoing and future clinical developments.

Expansion of CX-2051 Dose Trials

Initiated dose expansions at 7.2, 8.6, and 10 mg/kg, targeting enrollment of approximately 20 patients at each level, with updated data set expected in Q1 2026.

Pipeline Progress for CX-801

Dosed the first patient in the combination arm of the Phase I study with KEYTRUDA in metastatic melanoma. Initial translational data expected in Q4 2025.

Reduction in Operating Expenses

Operating expenses decreased to $19.9 million in Q2 2025 from $33.6 million in Q2 2024, driven by lower R&D and administrative costs.

CytomX Therapeutics (CTMX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CTMX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.05 / -	0.07	―	―	―
Aug 07, 2025	2025 (Q2)	-0.06 / 0.00	-0.08	―	―
May 12, 2025	2025 (Q1)	0.13 / 0.27	0.17	58.82% (+0.10)
Mar 06, 2025	2024 (Q4)	-0.20 / 0.22	0.02	1000.00% (+0.20)	―
Nov 07, 2024	2024 (Q3)	-0.17 / 0.07	0.04	75.00% (+0.03)	―
Aug 08, 2024	2024 (Q2)	-0.10 / -0.08	-0.02	-300.00% (-0.06)	―
May 08, 2024	2024 (Q1)	-0.10 / 0.17	-0.05	440.00% (+0.22)	―
Mar 11, 2024	2023 (Q4)	-0.05 / 0.02	-0.42	104.76% (+0.44)	―
Nov 07, 2023	2023 (Q3)	-0.19 / 0.04	-0.35	111.43% (+0.39)	―
Aug 08, 2023	2023 (Q2)	-0.19 / -0.02	-0.37	94.59% (+0.35)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CTMX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.10	$2.35	+11.90%
May 12, 2025	$0.93	$2.13	+129.03%
Mar 06, 2025	$0.62	$0.66	+6.45%
Nov 07, 2024	$1.00	$1.09	+9.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CytomX Therapeutics Inc. (CTMX) report earnings?

CytomX Therapeutics Inc. (CTMX) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is CytomX Therapeutics Inc. (CTMX) earnings time?

CytomX Therapeutics Inc. (CTMX) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CTMX EPS forecast?

CTMX EPS forecast for the fiscal quarter 2025 (Q3) is -0.05.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing